Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.40 |
| ▸ | BCL2 | P10415 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 4/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.36 |
| ▸ | PTPRC | P08575 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23408944 | 0.86 | RHEB (0.47) | HTR6MRGPRX4IDO1TACR1ROCK1 | |
| SCHEMBL25068973 | 0.83 | TACR1 (0.39) | HTR6MRGPRX4IDO1TACR1HTR2C | |
| SCHEMBL4323501 | 0.81 | HTR6 (0.52) | HTR6BCL2MCL1HTR2CMAPT | |
| SCHEMBL20905144 | 0.76 | TEAD1 (0.39) | HTR6MRGPRX4TACR1PTPN1PTPRC | |
| SCHEMBL23388229 | 0.75 | HTR6 (0.52) | HTR6 | |
| SCHEMBL23408961 | 0.73 | PTPN1 (0.39) | MRGPRX4IDO1TACR1PTPN1PTPRC | |
| SCHEMBL18362160 | 0.73 | HTR6 (0.48) | HTR6MCL1HTR2CPPARGPPARD | |
| SCHEMBL4395116 | 0.72 | HTR2C (0.49) | HTR6MCL1HTR2CPPARGPPARD | |
| SCHEMBL13228252 | 0.72 | HTR2C (0.65) | HTR6HTR2CMAPT | |
| SCHEMBL25068961 | 0.72 | TACR1 (0.40) | MRGPRX4IDO1TACR1HTR2CPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230055961-A1 | PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | DUNAD THERAPEUTICS LTD. (GB) | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230055961-A1 | PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | FURIN, PFAS, CFTR | HTR6 780/4885BCL2 1419/4885MCL1 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.